vs
安进（AMGN）与ORGANIGRAM GLOBAL INC.（OGI）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是ORGANIGRAM GLOBAL INC.的248905.5倍（$9.9B vs $39.6K）。安进净利率更高（13.5% vs -192.9%，领先206.4%）。安进自由现金流更多（$961.0M vs $-19.9K）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
Organigram Global Inc.是加拿大知名的医用及娱乐用大麻生产商，主营干花、可食用大麻制品、雾化产品及预卷烟等品类，核心市场为加拿大本土，目前正逐步拓展欧洲等海外区域市场。
AMGN vs OGI — 直观对比
营收规模更大
AMGN
是对方的248905.5倍
$39.6K
净利率更高
AMGN
高出206.4%
-192.9%
自由现金流更多
AMGN
多$961.0M
$-19.9K
损益表 — Q4 2025 vs Q3 2022
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $39.6K |
| 净利润 | $1.3B | $-76.5K |
| 毛利率 | 69.8% | — |
| 营业利润率 | 27.6% | -128.4% |
| 净利率 | 13.5% | -192.9% |
| 营收同比 | 8.6% | — |
| 净利润同比 | 112.6% | — |
| 每股收益（稀释后） | $2.45 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNOGI
| Q4 25 | $9.9B | — | ||
| Q3 25 | $9.6B | — | ||
| Q2 25 | $9.2B | — | ||
| Q1 25 | $8.1B | — | ||
| Q4 24 | $9.1B | — | ||
| Q3 24 | $8.5B | — | ||
| Q2 24 | $8.4B | — | ||
| Q1 24 | $7.4B | — |
净利润AMGNOGI
| Q4 25 | $1.3B | — | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $2.8B | — | ||
| Q2 24 | $746.0M | — | ||
| Q1 24 | $-113.0M | — |
毛利率AMGNOGI
| Q4 25 | 69.8% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 63.6% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.4% | — | ||
| Q1 24 | 57.0% | — |
营业利润率AMGNOGI
| Q4 25 | 27.6% | — | ||
| Q3 25 | 26.4% | — | ||
| Q2 25 | 28.9% | — | ||
| Q1 25 | 14.5% | — | ||
| Q4 24 | 25.4% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 22.8% | — | ||
| Q1 24 | 13.3% | — |
净利率AMGNOGI
| Q4 25 | 13.5% | — | ||
| Q3 25 | 33.7% | — | ||
| Q2 25 | 15.6% | — | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 6.9% | — | ||
| Q3 24 | 33.3% | — | ||
| Q2 24 | 8.9% | — | ||
| Q1 24 | -1.5% | — |
每股收益（稀释后）AMGNOGI
| Q4 25 | $2.45 | — | ||
| Q3 25 | $5.93 | — | ||
| Q2 25 | $2.65 | — | ||
| Q1 25 | $3.20 | — | ||
| Q4 24 | $1.17 | — | ||
| Q3 24 | $5.22 | — | ||
| Q2 24 | $1.38 | — | ||
| Q1 24 | $-0.21 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | — |
| 总债务越低越好 | $54.6B | — |
| 股东权益账面价值 | $8.7B | — |
| 总资产 | $90.6B | — |
| 负债/权益比越低杠杆越低 | 6.31× | — |
8季度趋势，按日历期对齐
现金及短期投资AMGNOGI
| Q4 25 | $9.1B | — | ||
| Q3 25 | $9.4B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $8.8B | — | ||
| Q4 24 | $12.0B | — | ||
| Q3 24 | $9.0B | — | ||
| Q2 24 | $9.3B | — | ||
| Q1 24 | $9.7B | — |
总债务AMGNOGI
| Q4 25 | $54.6B | — | ||
| Q3 25 | $54.6B | — | ||
| Q2 25 | $56.2B | — | ||
| Q1 25 | $57.4B | — | ||
| Q4 24 | $60.1B | — | ||
| Q3 24 | $60.4B | — | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
股东权益AMGNOGI
| Q4 25 | $8.7B | — | ||
| Q3 25 | $9.6B | — | ||
| Q2 25 | $7.4B | — | ||
| Q1 25 | $6.2B | — | ||
| Q4 24 | $5.9B | — | ||
| Q3 24 | $7.5B | — | ||
| Q2 24 | $5.9B | — | ||
| Q1 24 | $5.0B | — |
总资产AMGNOGI
| Q4 25 | $90.6B | — | ||
| Q3 25 | $90.1B | — | ||
| Q2 25 | $87.9B | — | ||
| Q1 25 | $89.4B | — | ||
| Q4 24 | $91.8B | — | ||
| Q3 24 | $90.9B | — | ||
| Q2 24 | $90.9B | — | ||
| Q1 24 | $93.0B | — |
负债/权益比AMGNOGI
| Q4 25 | 6.31× | — | ||
| Q3 25 | 5.67× | — | ||
| Q2 25 | 7.57× | — | ||
| Q1 25 | 9.24× | — | ||
| Q4 24 | 10.23× | — | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $-15.2K |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $-19.9K |
| 自由现金流率自由现金流/营收 | 9.7% | -50.2% |
| 资本支出强度资本支出/营收 | 6.5% | 11.8% |
| 现金转化率经营现金流/净利润 | 1.20× | — |
| 过去12个月自由现金流最近4个季度 | $8.1B | — |
8季度趋势，按日历期对齐
经营现金流AMGNOGI
| Q4 25 | $1.6B | — | ||
| Q3 25 | $4.7B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $3.6B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $689.0M | — |
自由现金流AMGNOGI
| Q4 25 | $961.0M | — | ||
| Q3 25 | $4.2B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $980.0M | — | ||
| Q4 24 | $4.4B | — | ||
| Q3 24 | $3.3B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $459.0M | — |
自由现金流率AMGNOGI
| Q4 25 | 9.7% | — | ||
| Q3 25 | 44.4% | — | ||
| Q2 25 | 20.8% | — | ||
| Q1 25 | 12.0% | — | ||
| Q4 24 | 48.4% | — | ||
| Q3 24 | 39.0% | — | ||
| Q2 24 | 26.5% | — | ||
| Q1 24 | 6.2% | — |
资本支出强度AMGNOGI
| Q4 25 | 6.5% | — | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 5.0% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 2.8% | — | ||
| Q1 24 | 3.1% | — |
现金转化率AMGNOGI
| Q4 25 | 1.20× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.59× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 7.61× | — | ||
| Q3 24 | 1.26× | — | ||
| Q2 24 | 3.30× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
OGI
| Unrealized gain on changes in fair value of biological assets (Note 7) | $20.1K | 51% |
| Other | $19.6K | 49% |
